2018年7月16日，中国，上海。 今天，位于中国上海的生物医药公司礼进生物宣布公司完成3000万美元的B轮融资。本次融资由通和毓承领投，其他投资方包括Winfair Global和润瓴资本。原有投资者Morningside Ventures也参与了本轮投资。 礼进生物由前艾伯维肿瘤研发资深科学家王结义博士于2016年创立，王结义博士在雅培/艾伯维工作二十二年，拥有丰富的抗癌新药及肿瘤免疫研发经验。礼进生物致力于发明创造拥有自主知识产权, 针对肿瘤等重大疾病的新药。其拥有世界领先的交联抗体技术平台以及优化刺激性抗体，尤其是其独有的xLinkAb（交联抗体）技术能够有选择性地激活肿瘤微环境特定受体，减少正常组织免疫副反应。公司重点研发世界领先的肿瘤免疫激活性抗体和癌症免疫组合治疗，以期可以提高癌症病人长期生存率。目前礼进生物抗PD-1人源化单克隆抗体SSI-361已授权安科生物开发中国市场。
“我们认为礼进生物是一个极具潜力的投资机会。礼进生物独有的交联抗体技术平台可以有效解决当前肿瘤免疫疗法中出现的副反应问题，并进一步实现对某类受体的选择性特异激活，有望进一步拓展肿瘤免疫疗法的靶标以及适应范围”，通和毓承首席执行官兼创始合伙人陈连勇博士表示：“相信公司在王结义博士的带领下，可以为肿瘤患者带来更多疗效好副作用低的免疫治疗药物。”
本轮融资的资金会用于推动礼进生物目前研发管线中数个具有竞争力的全新的肿瘤免疫治疗分子的临床前开发以及未来进入临床开展临床试验。礼进生物还将利用募集得到的资金进一步拓展其交联抗体技术平台的能力，研发更多相关适应症的全新免疫疗法。本轮募资的顺利完成也显示出投资人对于礼进生物拥有的巨大潜力，以及对公司领导层为患者和投资人回馈能力的信心。 通和毓承也将一如既往的加强对于领域内革新性技术的投资，加快推进相关药物以及疗法的开发与临床实验。我们期待通过资本的助力，可以帮助礼进生物进一步释放其研发能力，为癌症免疫治疗引入全新的药物以及治疗方案！
关于通和毓承资本
通和毓承是一家专注于医疗健康领域的领先投资机构，对中美两地市场均有深度聚焦和广泛覆盖。通和毓承拥有近40人的专业投资和运营管理团队，在中国上海、香港和美国波士顿、帕罗奥多设有办公室。目前共管理4支美元基金及3支人民币基金，总管理资金规模逾百亿人民币，迄今累计投资和培育了逾70家企业。通和毓承由两家专业且互补，辐射中美两地的医疗健康领域投资机构通和资本和毓承资本在2017年5月合并而成。合并后的通和毓承是行业内规模最大的专业投资机构之一，成为推动跨太平洋两岸生命科学及医疗健康领域内创新型投资机会的有力引擎。
July 16th 2018, Shanghai, China.
Lyvgen Biopharma, a biotechnology company developing novel immunotherapies based in Shanghai, today announced the completion of a USD $30 million Series B funding round. 6 Dimensions Capital led this round of financing, with participation from Winfair Global, Runling Capital and existing Series A investor Morningside Ventures.
Lyvgen was founded in 2016 by Dr. Jieyi Wang, who most recently served as the Senior Principal Research Scientist at AbbVie. Dr. Wang brings over 22 years of experience from Abbott and AbbVie, and is a seasoned veteran in oncology and immunotherapy research. With Lyvgen’s industry leading cross-link antibody (xLinkAb) platform and co-stimulation agonist antibodies, the company is dedicated to developing first-in-class and best-in-class therapeutics for major diseases, such as cancer. Lyvgen’s xLinkAb technology could selectively activate specific receptors in the tumor microenvironment, while reducing immune-related adverse effects in the healthy tissue. Currently, the company is focused on developing combination therapy of tumor immune agonist antibody and cancer immunotherapy, in an effort to improve the long-term survival of cancer patients. Lyvgen has out-licensed its anti-PD-1 humanized monoclonal antibody product SSI-361 to Anhui Anke Biotechnology for market development in China. “We believe Lyvgen presents an investment opportunity with high potential. Its proprietary cross-link antibody platform could solve the toxicity issue in current cancer immunotherapies and enable selective activation of specific groups of receptors. These unique advantages could help the company expand the target and indication for cancer immunotherapy.” Dr. Leon Chen, CEO and Founding Partner of 6 Dimensions Capital, stated, “We believe that under the leadership of Dr. Wang, Lyvgen could develop more efficacious and better tolerated immunotherapies for cancer patients.” Proceeds from this financing will support the pre-clinical and future clinical studies for several promising immuno-oncology programs in Lyvgen’s pipeline. Lyvgen will also use funding from this round to further expand the capability of its cross-link antibody platform for immunotherapies in more suitable indications. The successful completion of this financing round demonstrated confidence from its investors in Lyvgen’s potential and in its leadership team to deliver value to patients and investors. 6 Dimensions Capital will continue to invest in innovative healthcare technologies to propel the pre-clinical and clinical studies of innovative therapeutics. With investment in this round, we hope to help Lyvgen unleash its potential and develop novel immunotherapies. About 6 Dimensions Capital
6 Dimensions Capital is a leading healthcare focused investment firm with an in-depth focus and extensive coverage across China and the United States. It consists of a team of about 40 investment and operation professionals with offices in Shanghai, Hong Kong, Boston, and Palo Alto. The firm currently has US$1.6 billion assets under management through 4 US dollar-denominated and 3 RMB-denominated funds and has cultivated a portfolio of more than 70 companies.
6Dimensions Capital was formed in May 2017 through the merger of Frontline BioVentures and WuXi Healthcare Ventures, two prominent and complementary China-U.S. healthcare investment firms. The merger has created a powerhouse that aims to fund innovation in an optimal position to capture the biggest value appreciation on both sides of the Pacific.
关于煜森资本 煜森资本成立于2016年，聚焦国际先进的生物医学科技，旨在打造一流的医疗健康创业和投融资平台。核心团队由一批业内资深企业家、投资人和职业经理人组成，拥有丰富的研发、管理、创业、投资和资本运作经验，并拥有深厚的行业资源。煜森资本核心业务，包括天使投资、共同创业、财务顾问和专项投资基金四大板块。煜森资本秉承“投资并与企业共成长”的理念，致力于成为企业的紧密合作伙伴，推动和协助企业共同发展，与投资和服务的企业携手构建中国医疗健康新生态。
